For the quarter ending 2026-03-31, LRMR had $92,501K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Operating expenses | 31,117 | 172,497 | - | - |
| Other income, net | 1,504 | 6,824 | - | - |
| Net loss | -29,613 | -110,210 | - | -55,463 |
| Stock-based compensation expense | 1,979 | 3,342 | - | 3,662 |
| Lease expense | -85 | -148 | - | -133 |
| Depreciation expense | 64 | 175 | - | 175 |
| Amortization of premium on marketable securities | -80 | -482 | - | -1,216 |
| Prepaid expenses and other current assets | -578 | -1,862 | - | -4,818 |
| Accounts payable | 2,925 | 1,070 | - | 1,722 |
| Accrued expenses | -20,401 | 37,073 | - | 479 |
| Other assets | -19 | -38 | - | -35 |
| Net cash used in operating activities | -44,614 | -67,280 | - | -45,921 |
| Purchases of property and equipment | - | 23 | - | 68 |
| Purchases of marketable securities | - | 3,458 | - | 80,142 |
| Maturities of marketable securities | 29,000 | 70,500 | - | 113,500 |
| Net cash provided by (used in) investing activities | 29,000 | 67,019 | - | 33,290 |
| Proceeds from issuance of equity securities | 108,101 | - | - | - |
| Proceeds from issuance of common stock, net of issuance costs | - | 65,086 | - | - |
| Proceeds from exercise of stock options | 14 | - | - | - |
| Net cash provided by financing activities | 108,115 | 65,086 | - | 0 |
| Net increase in cash, cash equivalents and restricted cash | 92,501 | -4,728 | 69,553 | -12,631 |
| Cash, cash equivalents and restricted cash at beginning of period | 86,018 | 90,746 | 33,824 | - |
| Cash, cash equivalents and restricted cash at end of period | 178,519 | 86,018 | 90,746 | - |
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)